Results 21 to 30 of about 66,137 (309)

Preparation and Evaluation of Amino Acid Conjugates of Celecoxib as Prodrugs to Improve the Pharmacokinetic and Therapeutic Properties of Celecoxib

open access: yesPharmaceutics, 2020
Although celecoxib is quite effective in the management of inflammation-related diseases, especially arthritis, its use is limited by concerns including low bioavailability (BA), non-linear pharmacokinetic (PK) profile, and peak concentration-related ...
Yonghyun Lee   +4 more
doaj   +1 more source

The Efficacy and Safety of Celecoxib in Addition to Standard Cancer Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

open access: yesCurrent Oncology, 2022
The purpose of this meta-analysis was to evaluate the efficacy and safety of celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, in addition to standard anticancer therapy. Randomized controlled trials (RCTs) that evaluated the efficacy and safety
Shi-Yu Ye   +10 more
doaj   +1 more source

Screening for autophagy/hypoxia/ferroptosis/pyroptosis-related genes of tendon injury and repair in a rat model after celecoxib and lactoferrin treatment

open access: yesJournal of Orthopaedic Surgery and Research, 2023
Background Tendon injuries are among the most common musculoskeletal disorders. Celecoxib possesses an effective anti-inflammatory activity in the tendon injury treatment. Lactoferrin has a great potential for the tendon regeneration.
Yaonan Zhang   +6 more
doaj   +1 more source

Towards safer anti-inflammatory therapy: synthesis of new thymol–pyrazole hybrids as dual COX-2/5-LOX inhibitors

open access: yesJournal of Enzyme Inhibition and Medicinal Chemistry, 2023
New thymol − 1,5-disubstitutedpyrazole hybrids were synthesised as dual COX-2/5-LOX inhibitors. Compounds 8b, 8g, 8c, and 4a displayed in vitro inhibitory activity against COX-2 (IC50 = 0.043, 0.045, 0.063, and 0.068 µM) nearly equal to celecoxib (IC50 =
Mostafa M. M. El-Miligy   +5 more
doaj   +1 more source

Celecoxib-induced cytotoxic effect is potentiated by inhibition of autophagy in human urothelial carcinoma cells. [PDF]

open access: yesPLoS ONE, 2013
Celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, can elicit anti-tumor effects in various malignancies. Here, we sought to clarify the role of autophagy in celecoxib-induced cytotoxicity in human urothelial carcinoma (UC) cells.
Kuo-How Huang   +12 more
doaj   +1 more source

Etanercept/celecoxib on improving MRI inflammation of active ankylosing spondylitis: A multicenter, open-label, randomized clinical trial

open access: yesFrontiers in Immunology, 2022
ObjectiveTo investigate the efficacy and safety of clinical, magnetic resonance imaging (MRI) changes in active ankylosing spondylitis (AS) patients with etanercept and celecoxib alone/combined treatment.MethodsA randomized controlled trial was conducted
Liudan Tu   +16 more
doaj   +1 more source

Explainable Artificial Intelligence for Pharmacovigilance: What Features Are Important When Predicting Adverse Outcomes? [PDF]

open access: yes, 2021
Explainable Artificial Intelligence (XAI) has been identified as a viable method for determining the importance of features when making predictions using Machine Learning (ML) models. In this study, we created models that take an individual's health information (e.g.
arxiv   +1 more source

Celecoxib for rheumatoid arthritis [PDF]

open access: yesCochrane Database of Systematic Reviews, 2016
Rheumatoid arthritis is a systemic auto-immune disorder that causes widespread and persistent inflammation of the synovial lining of joints and tendon sheaths. Presently, there is no cure for rheumatoid arthritis and treatment focuses on managing symptoms such as pain, stiffness and mobility, with the aim of achieving stable remission and improving ...
Mahir Fidahic   +3 more
openaire   +3 more sources

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

open access: yesJournal of the American Medical Association (JAMA), 2000
CONTEXT Conventional nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with a spectrum of toxic effects, notably gastrointestinal (GI) effects, because of inhibition of cyclooxygenase (COX)-1.
F. Silverstein   +15 more
semanticscholar   +1 more source

The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.

open access: yesNew England Journal of Medicine, 2000
BACKGROUND Patients with familial adenomatous polyposis have a nearly 100 percent risk of colorectal cancer. In this disease, the chemopreventive effects of nonsteroidal antiinflammatory drugs may be related to their inhibition of cyclooxygenase-2 ...
G. Steinbach   +23 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy